Five Discovery is a biotechnology company developing non-hallucinogenic neuroplastogens — psychedelic-inspired compounds that promote the repair and stabilization of dysfunctional brain circuits, without producing a psychedelic experience. Our approach draws on the neuroscience of psychedelic molecules to engineer therapeutics optimized purely for neurological benefit.

Our lead program targets Levodopa-Induced Dyskinesia, a common and debilitating motor complication in medicated Parkinson’s patients for which no neuroplasticity-based treatment currently exists. Our longer-term vision extends to Parkinson’s disease itself and other neurodegenerative conditions.

Five Discovery was founded on the conviction that functional brain repair represents one of the most important and underexplored frontiers in psychedelic-inspired medicine — and that the field’s potential reaches far beyond mood disorders and mental health. We are building the scientific and clinical foundation to lead in that space.